Sprifermin

Summary

Sprifermin (rhFGF-18) is a recombinant truncated form of human fibroblast growth factor 18 under clinical investigation for the intra-articular treatment of knee osteoarthritis. It has demonstrated dose-dependent increases in total and central femorotibial cartilage thickness in Phase II trials (FORWARD trial), with ongoing evaluation of its clinical symptomatic benefit and disease-modifying potential.

Mechanism of Action

Selectively binds and activates FGFR3 (and to a lesser extent FGFR1) on chondrocytes, stimulating chondrocyte proliferation and cartilage matrix synthesis, thereby promoting cartilage regeneration and potentially slowing structural progression of osteoarthritis.

Routes of Administration

Goals & Uses

• Cartilage thickness increase in knee osteoarthritisStructural / Disease ModifyingModerate
• Symptomatic relief of knee osteoarthritis (pain/function)SymptomaticLow
• Disease-modifying osteoarthritis drug (DMOAD)Disease ModificationModerate

Contraindications

• Active joint infection or septic arthritisInfectiousHigh
• Active malignancy or history of malignancy near jointOncologicHigh
• Known hypersensitivity to sprifermin or FGF-18ImmunologicHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

• Anti-drug antibodies (immunogenicity)ImmunologicUncommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• Nasopharyngitis / upper respiratory infectionInfectiousUncommon
• Injection site reactions (arthralgia, swelling, effusion)Local/musculoskeletalCommon

Drug Interactions

• Intra-articular corticosteroidsModerate
• Heparin / heparin-like compoundsLow

Population Constraints

• Patients with active or recent malignancyOncologicRelative
• Pediatric patientsAgeRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Severely immunocompromised patientsImmunologicalRelative

Regulatory Status

• European UnionInvestigationalDeveloped by Merck KGaA (European entity); EMA approval not granted. Clinical trials conducted under CTA.
• United StatesInvestigationalInvestigated under IND; not FDA-approved. Phase II completed; Phase III pathway not confirmed as of knowledge cutoff.
• United KingdomInvestigationalNo MHRA approval; investigational status mirrors EU classification.

Not approved by FDA, EMA, or any major regulatory authority as of knowledge cutoff. Investigated under IND/CTA frameworks. Merck KGaA/EMD Serono are the primary developers. Phase II results published; Phase III development status uncertain.

Evidence & Sources

No sources recorded yet.